2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Lymphoma, T-Cell, Peripheral
16
Lymphoma, T-Cell
10
Recurrence
7
Lymphoma
6
Lymphoma, Non-Hodgkin
5
Lymphoma, Large-Cell, Anaplastic
5
Immunoblastic Lymphadenopathy
4
Mycosis Fungoides
3
Lymphoma, T-Cell, Cutaneous
3
Lymphoma, Follicular
3
Hodgkin Disease
3
Carcinoma, Non-Small-Cell Lung
3
Waldenstrom Macroglobulinemia
2
Unspecified Adult Solid Tumor, Protocol Specific
2
Sezary Syndrome
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell
2
Lung Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Burkitt Lymphoma
2
Adenocarcinoma Of Esophagus
2
Urinary Bladder Neoplasms
1
Subcutaneous panniculitis-like T-cell lymphoma
1
Stomach Neoplasms
1
Smoking
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Interventions
Rituximab
161
Cyclophosphamide
142
fludarabine phosphate
89
Peripheral Blood Stem Cell Transplantation
81
Filgrastim
59
Mycophenolic Acid
58
Whole-Body Irradiation
53
Cyclosporine
53
Radiotherapy
52
Lenalidomide
47
Busulfan
45
Tacrolimus
44
Etoposide
43
Antilymphocyte Serum
41
Melphalan
37
Methotrexate
31
fludarabine
30
Bortezomib
30
Prednisone
28
Bendamustine Hydrochloride
28
Cytarabine
24
Cord Blood Stem Cell Transplantation
23
obinutuzumab
22
Vincristine
22
Methylprednisolone
21
Flow Cytometry
21
ibrutinib
19
venetoclax
18
sargramostim
17
Granulocyte Colony-Stimulating Factor
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, B-Cell, Marginal Zone
×
10-propargyl-10-deazaaminopterin
×
Clear all
NCT01947140
2022-11-23
PDX+Romi
Columbia University
Phase 1/2
Completed
57 enrolled